Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Stock Short Interest Rises 5,382.3%

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 451,633 shares, a growth of 5,382.3% from the August 31st total of 8,238 shares. Based on an average daily trading volume, of 4,671,517 shares, the days-to-cover ratio is currently 0.1 days. Currently, 163.6% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Scinai Immunotherapeutics has a consensus rating of “Sell”.

Scinai Immunotherapeutics Stock Performance

NASDAQ SCNI opened at $1.86 on Friday. Scinai Immunotherapeutics has a twelve month low of $1.43 and a twelve month high of $16.30. The company has a quick ratio of 1.35, a current ratio of 1.56 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.32 million, a price-to-earnings ratio of -0.02 and a beta of 2.08. The business has a 50-day moving average price of $2.33 and a 200-day moving average price of $4.00.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company is developing treatments designed to target disease-related immune pathways while potentially providing localized delivery and reduced systemic exposure.

Scinai’s development platform is based on NanoAbs, or nanobodies, which are small antibody-derived molecules intended to bind selectively to therapeutic targets.